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OBJECTIVES The purpose of this study was to test the hypothesis that endothelin (ET) receptor
antagonism reduces coronary vasa vasorum neovascularization in experimental hypercholes-
terolemia.
BACKGROUND Experimental hypercholesterolemia is associated with increased expression of ET-1, an
endothelium-derived peptide with vasoconstricting, mitogenic and angiogenic properties, in
the coronary arterial wall as well as with vasa vasorum neovascularization. A pathomechanistic
role of the endogenous ET system in vasa vasorum neovascularization in hypercholesterol-
emia has, however, remained uncertain so far.
METHODS Female domestic pigs were placed on a normal diet (N; n  7) or on a hypercholesterolemic
diet without (HC; n  6) or with ET-A receptor antagonism (ABT-627, 4 mg/kg/day;
HC  ET-A; n  6). After 12 weeks, coronary vasa vasorum structure was assessed by
three-dimensional microscopic computed tomography, expression of vascular endothelial
growth factor (VEGF) within the coronary arterial wall by Western blotting and immuno-
staining.
RESULTS Compared with the N group, plasma concentrations of low-density lipoprotein cholesterol
were higher in both the HC and HC  ET-A groups (36  3 mg/dl vs. 312  153 mg/dl
and 303  113 mg/dl, p  0.01). Vasa vasorum density was higher in the HC group
compared with the N group (4.7  1.8 per mm2 vs. 2.5  1.5 per mm2; p  0.05) and was
preserved in the HC  ET-A group (3.2  0.7 per mm2). In parallel, increase in VEGF
expression in the coronary arterial wall in the HC group was preserved in the HC  ET-A
group.
CONCLUSIONS The current study demonstrates that chronic endothelin receptor antagonism prevents the
increase in VEGF expression and vasa vasorum density of coronary arteries in experimental
hypercholesterolemia. These findings support a role for the endogenous ET system in vasa
vasorum neovascularization in early coronary atherosclerosis. (J Am Coll Cardiol 2002;39:
1555–61) © 2002 by the American College of Cardiology Foundation
The three members of the family of endothelins are pro-
duced in a variety of tissues and are involved in the
regulation of vasomotoric tone and cell proliferation (1).
Notably, endothelin-1 (ET-1), the 21-amino acid peptide
produced by endothelial cells, has been implicated in endo-
thelial dysfunction in atherosclerosis and in neovasculariza-
tion in malignancies (2,3). Within the vasculature, these
effects of ET-1 are mediated by endothelin-A (ET-A)
receptors on vascular smooth muscle cells and endothelin-B
(ET-B) receptors on both vascular smooth muscle cells and
endothelial cells (1,2).
Various factors such as the renin-angiotensin system
(RAS) modulate the activity of the endogenous endothelin
system, whereby angiotensin II (Ang II) stimulates the
expression of both ET-1 and ET-A receptors (4–7). Of
note, ET-A receptor antagonism inhibits this activation
pathway of the endogenous endothelin system and reduces
ET-1 vascular tissue levels (8,9). In cardiovascular disease
and malignancies, endothelin receptor antagonism preserves
biological integrity and reduces tumor neovascularization,
respectively (3,10,11).
Experimental hypercholesterolemia is associated with
enhanced vasoconstriction of the coronary circulation in
association with increased vascular tissue expression of
ET-1 (10–12). Moreover, using a novel imaging technique,
we demonstrated that experimental hypercholesterolemia is
also associated with an increase in the spatial density of
coronary vasa vasorum (13,14). Notably, this neovascular-
ization process occurs very early in the atherosclerotic
process and before epicardial endothelial dysfunction (15).
Given the mitogenic effect of ET-1 upon endothelial cells
(16), the stimulatory effect of ET-1 upon the release of
vascular endothelial growth factor (VEGF) from vascular
smooth muscle cells (17) and the correlation of ET-1
expression with microvessel density in tumor neovascular-
ization (18), the endogenous endothelin system might
potentially be involved in vasa vasorum neovascularization
in early atherosclerosis. Thus, this study was designed to test
the hypothesis that chronic endothelin receptor antagonism
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will preserve coronary vasa vasorum neovascularization in
experimental hypercholesterolemia.
METHODS
Animals. The study was reviewed and approved by the
Mayo Foundation Institutional Animal Care and Use Com-
mittee. For a study period of 12 weeks, female domestic pigs
(weight: 25 kg to 35 kg) were placed on a normal chow diet
(N; n  7), on a hypercholesterolemic diet containing 2%
cholesterol and 15% lard (TD 93296, Harlan Teklad,
Madison, Wisconsin) (HC; n  6) or on a hypercholester-
olemic diet supplemented with selective ET-A receptor
antagonism (HC  ET-A; n  6) by weight-adapted, oral
application of ABT-627 (4 mg/kg per day, Abbott Labo-
ratories, Abbott Park, Illinois) as described in detail before
(10,11). ABT-627 is the active R,R,S isomer of the racemic
compound A-127722, acting as a competitive inhibitor of
ET-1 with about 2,000 higher affinity for the ET-A than
for the ET-B receptor (Ki values of 69 pM and 139 nM for
the ET-A and ET-B receptor, respectively) (19). At the end
of each study period, blood samples were taken for analysis
of plasma lipid levels, followed by euthanization of the
animals (10,11). The hearts were immediately harvested and
placed in a cold, modified Krebs-Ringer bicarbonate solu-
tion (10,11).
Microcomputed tomography imaging. The left anterior
descending coronary artery was prepared and scanned by
microcomputed tomography as described by our group in
detail before (13–15). The imaging system yielded a matrix
of 42 m cubic voxels with a 16 bits gray scale and an
average number of 500 slices per coronary artery segment for
analysis (13–15). The resulting three-dimensional digi-
talized image was analyzed by using the Analyze software
package (Biomedical Imaging Resource, Mayo Foundation,
Rochester, Minnesota) (15).
All specimens were traced over their entire length, and
cross-sections were analyzed at 1-mm intervals. Areas of
potential source of error, such as branching points, were
excluded from the analysis. Thus, six to 12 topographic
cross-sections were analyzed for each specimen, on average.
As reported before, vasa vasorum area was determined in
each cross-section and designated vessel wall area
(14,15,20,21). Vasa vasorum were manually traced and
measured in this area, yielding the following parameters for
each cross-section: vessel wall area, vasa vasorum count and
vasa vasorum density (i.e., vasa vasorum per mm2 vessel wall
area), mean diameter of first and second order vasa vasorum
and ratio of the number of second to first order vasa
vasorum. First order vasa vasorum originated from the main
coronary lumen and ran longitudinally to the coronary
artery. Second order vasa vasorum originated from first
order vasa vasorum and ran circumferentially around the
lumen (14). Data analysis was performed in standardized,
nonblinded manner among all experimental groups. Mean
values were obtained for each individual animal, and data
presentation per group was based on these values. Overall,
the mean coefficients of variation for vessel wall area, vasa
vasorum count and vasa vasorum density were 0.13, 0.45
and 0.38, respectively, without any significant differences
among the groups.
Immunohistochemistry. After deparaffinization in xylene
and rehydration in 100%, 95% and 70% ethanol, porcine
coronary artery slides were incubated with equimolar 3%
H2O2/100% MeOH solution to block endogenous tissue
peroxidase activity. Anti-VEGF primary antibody (dilution
of 1:100, 4°C overnight, Santa Cruz Biotechnology Inc.,
Santa Cruz, California) was detected with the EnVision kit
(Dako Corporation, Carpinteria, California) in peroxidase-
labeling technique and 3,3-diaminobenzidine tetra-
hydrochloride (DAB) as chromogen (Vector Laboratories
Inc., Burlingame, California) to yield a brownish reaction
product. Incubation with an unspecific isotype antibody
served as a control for the specificity of immunoreactivity.
All sections were counterstained with hematoxylin.
Double-label immunohistochemistry. Double-label im-
munostaining of coronary artery specimens was performed
using the EnVision Doublestain Kit (Dako). In the first
step, anti-VEGF antibody (Santa Cruz) was detected by a
peroxidase-labeled secondary antibody with DAB as chro-
mogen (Vector Laboratories). In the second step, anti-
smooth muscle alpha-actin (dilution 1:1500; Dako) anti-
body was detected by an alkaline phosphatase-labeled
secondary antibody with Vector Red as chromogen (Vector
Laboratories). Endogenous alkaline phosphatase was
blocked by incubation with levamisole (Dako). All sections
underwent counterstaining with hematoxylin.
Western blot. After removal of the heart, coronary arteries
were snap frozen in liquid nitrogen and stored at 80°C
until further processing. All tissues were homogenized using
a tissue homogenizer and a lysis buffer of the following
composition: 50 nM Tris HCl, pH 8.0, 150 mM NaCl,
0.02% Sodium Azide, 0.1% SDS, PMSF 100 g/ml,
Aprotinin 1 g/ml 1% NP-40, 0.5% sodium deoxycholate.
The lysate was analyzed for protein content using a Brad-
ford assay (Bio-Rad Laboratories, Hercules, California),
and equal amounts of protein were resolved under reducing
conditions on an 8% SDS-polyacrylamide gel. Immuno-
Abbreviations and Acronyms
Ang II  angiotensin II





HC  high cholesterol diet
HC  ET-A  high cholesterol diet plus ET-A
antagonist
N  normal diet
RAS  renin-angiotensin system
VEGF  vascular endothelial growth factor
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blotting was performed using an anti-VEGF antibody
(Santa Cruz) at a dilution of 1:500 in a nonfat milk/Tris
buffer. The polyvinylidene diflouride membrane was subse-
quently probed with a secondary anti-mouse antibody con-
jugated to horseradish peroxidase (dilution of 1:2000; Am-
ersham, Piscataway, New Jersey) and developed with
chemiluminescence (Pierce, Rockford, Illinois). After expo-
sure of the membrane to an X-ray film (Eastman Kodak
Company, Rochester, New York) and film development,
analysis of optical density of immunoblots was performed
using NIH image, and the results were presented in densi-
tometric units.
Statistical analysis. All continuous data are expressed as
mean  SD. Data comparison among three study groups
was based on analysis of variance with respective all pairwise
multiple comparison post-hoc analysis for parametric (Bon-
ferroni t test) and nonparametric (Dunn’s method) data.
Either unpaired t test (parametric data) or U test (nonpara-
metric data) was used for data comparison between two
groups. Statistical significance was accepted for p  0.05.
RESULTS
Animals. Compared with N animals, plasma lipid concen-
trations were higher in the HC and HC  ET-A animals
(total cholesterol: 84  3 mg/dl, 497  164 mg/dl, 428 
124 mg/dl; LDL: 36  3 mg/dl, 312  153 mg/dl, 303 
113 mg/dl; HDL: 41  5 mg/dl, 99  38 mg/dl, 117 
13 mg/dl; p  0.05 N vs. HC and HC  ET-A for total
cholesterol, low-density lipoprotein and high-density li-
poprotein). No significant difference in systemic hemody-
namics was observed between the groups (11).
Microcomputed tomography imaging. Vasa vasorum
count and vasa vasorum density were higher in the HC than
in N pigs but similar in the HC ET-A and N pigs (Table
1). In N pigs, the spatial distribution pattern of coronary
vasa vasorum was clearly structured into first order vasa
vasorum, which run longitudinally to the main lumen, and
second order vasa vasorum, which run circumferentially
around the main lumen. In HC animals, this characteristic
structure was abolished, whereas, in HC  ET-A pigs, the
spatial distribution pattern of coronary vasa vasorum was
similar to N animals (Fig. 1).
Immunohistochemistry. Immunoreactivity for VEGF was
present predominantly in the outer media and, to a lesser
extent, in the adventitia. In the adventitia, VEGF immu-
noreactivity co-localized with endothelial cells of the vasa
vasorum in all groups but was also found in the connective
tissue in the adventitial area adjacent to the media in HC
animals. In this study group, immunoreactivity for VEGF
was most intense and co-localized preferentially with vas-
cular smooth muscle cells in the outer media (Fig. 2).







Vessel diameter (mm) 1.8  0.5 1.9  0.5 1.9  0.3
Lumen area (mm2) 2.6  1.2 2.9  1.3 3.0  0.8
Vessel wall area (mm2) 1.8  0.7 2.8  1.3 2.1  0.5
Vasa vasorum count (n) 4.9  3.6 11.7  4.7* 6.7  2.3
Vasa vasorum/vessel wall
area (n/mm2)
2.5  1.5 4.7  1.8* 3.2  0.7
Vasa vasorum/lumen
area (n/mm2)
1.7  1.1 4.5  1.3† 2.2  0.4
Ratio 2nd/1st order vasa
vasorum
2.6  2.0 3.7  1.3 2.3  1.9
Diameter 1st order vasa
vasorum (m)
96  32 93  12 81  10
Diameter 2nd order vasa
vasorum (m)
62  6 55  6 58  7
N, HC, HC  ETA  animals fed a normal diet or a high-cholesterol diet without
or with endothelin-type A-receptor antagonism for 12 weeks, respectively.
Parameter values are mean  SD; *p  0.05 vs. N; †p  0.05 vs. N and HC 
ET-A.
Figure 1. Representative microcomputed tomography images of the prox-
imal segments of the left anterior descending artery from animals fed a
normal diet (N) (left panel) or high cholesterol diet without (HC) (middle
panel) or with endothelin-type A-receptor antagonism (HC  ET-A)
(right panel) for 12 weeks. The spatial distribution pattern of vasa vasorum
in the N group is characterized by a clear structure into first order vasa
vasorum, running longitudinally and second order vasa vasorum, running
circumferentially. In the HC group, a plexus of newly formed vasa vasorum
and in the HC ET-A group a restitution to a normal status are apparent.
Illustration voxel size 21 m.
1557JACC Vol. 39, No. 9, 2002 Herrmann et al.
May 1, 2002:1555–61 ET Antagonism and Vasa Vasorum Neovascularization
Western blotting. Quantitative analysis by Western blot-
ting demonstrated that the amount of VEGF within the
coronary arterial wall was higher in the HC group than in
the N group and significantly lower in HC  ET-A pigs
than in HC pigs (p  0.05) (Fig. 3).
DISCUSSION
The principal finding of this study is that chronic antago-
nism of the endothelin type A receptor prevents the increase
in the spatial density of vasa vasorum of epicardial arteries in
experimental hypercholesterolemia. This effect of ET-A
antagonism upon vasa vasorum structure was associated
with similar preservation of VEGF expression in the coro-
nary arterial wall and was observed without changes in
plasma lipid values. Thus, this study supports a role for the
endogenous endothelin system in the development of cor-
onary vasa vasorum neovascularization in early coronary
atherosclerosis.
Endothelin and tumor neovascularization. Increased tis-
sue levels of ET-1 have been demonstrated in a variety of
different tumors, and ET-1 has been identified as an
autocrine growth factor and angiogenic factor in these
tissues (3). Moreover, the expression of ET-1 in tumor
Figure 2. Double-immunostaining for smooth muscle cell alpha-actin (red) and VEGF (brown) of histologic cross-sections of coronary arteries from
animals fed a normal diet (N) (A and B) or high cholesterol diet without (HC) (C and D) or with endothelin-type-A receptor antagonism (HC  ET-A)
(E and F) for 12 weeks. In contrast with the other two groups, intense vascular endothelial growth factor immunoreactivity is apparent in the outer media
and adjacent adventitia in the HC group, including vasa vasorum (arrow in D). Original magnification for (A) 37.5, for (B) 62.5, for (C) 62.5, for
(D) 125, for (E) 62.5 and for (F) 100.
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tissue has been shown to correlate with malignancy and
vascularity in colorectal cancer and brain tumors (3). Salani
et al. (18) reported on the correlation between tumor
microvessel count and ET-1 expression in ovarian carci-
noma. Furthermore, they found a correlation between ET-1
and VEGF expression in these tissues, as assessed by the use
of immunohistochemical methods, and suggested that both
ET-1 and VEGF contribute to tumor neovascularization
(18). Indeed, in in-vitro studies, they clearly demonstrated
that ET-1 enhances VEGF-induced neovascularization
(18,22). Of note, stimulation of VEGF production of
ovarian carcinoma cells by ET-1 was completely blocked by
an ET-A antagonist (18). Thus, a role for the endogenous
endothelin system in tumor neovascularization has been
increasingly recognized during recent years.
Endothelin and coronary neovascularization. Increase in
tissue expression of ET-1 has also been described in the
vascular wall in preatherosclerotic and atherosclerotic dis-
ease states, including experimental hypercholesterolemia
(12). As with tumor vessels, it has been shown that vascular
smooth muscle cells of macro- and microvessels of the
coronary circulation express both ET-A and ET-B recep-
tors, whereas endothelial cells exclusively express ET-B
receptors (23,24). In addition to a direct mitogenic effect
upon endothelial cells, mediated by the ET-B receptor, in-
vitro studies demonstrated that ET-1 can lead to endothe-
lial cell proliferation, migration and invasion of the extra-
cellular matrix by stimulation of the synthesis of VEGF in
vascular smooth muscle cells, mediated by the ET-A recep-
tor (17,25,26). In this study, coronary artery expression of
VEGF increased during experimental hypercholesterolemia,
predominantly in the smooth muscle cell layer of the media.
Of note, this increase in VEGF expression by medial
smooth muscle cells was prevented by ET-A receptor
antagonism as was increase in spatial density of coronary
vasa vasorum during experimental hypercholesterolemia.
Thus, this study, for the first time, supports a pathophysi-
ologic role for the endogenous endothelin system in coro-
nary vasa vasorum neovascularization in experimental hy-
percholesterolemia.
Endothelin, the RAS and oxidative stress. The role of
other vasoactive peptides cannot be ruled out. In this regard,
an important role in the regulation of ET-1 expression has
been attributed to the RAS (4,27). Indeed, experimental
hypercholesterolemia is characterized by an increase in the
expression of angiotensin type 1 receptor and, therefore, by
an enhancement of the Ang II pathway on vascular tissue
level (28). Given the stimulatory action of Ang II upon the
Figure 3. Bar graph illustrating vascular endothelial growth factor expression in the coronary arterial wall from animals fed a normal diet (N, n  4) or
high cholesterol diet without (HC, n 3) or with endothelin-type-A receptor antagonism (HC ET-A, n 3) for 12 weeks. Vascular endothelial growth
factor protein content was higher in the HC group than in the N group (p 0.06) and significantly lower in the HC ET-A group than in the HC group.
*p  0.05. Values are mean  standard error.
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expression of ET-1, this might translate into an increase in
vascular tissue levels of ET-1, which has, in fact, been
demonstrated in prior in-vivo studies (8,9). Importantly,
ET-A receptor antagonism abolishes this stimulatory action
of Ang II and reduces vascular tissue levels of ET-1 (8,9).
Furthermore, the local RAS might stimulate vascular tissue
expression of ET-1 by increase in endogenous oxidative
stress (29–31). Thus, by virtue of the fact that ET-1 is a
potent stimulator of VEGF expression, ET-A receptor
antagonism might prevent an increase in vascular tissue
expression of VEGF and an increase in vasa vasorum spatial
density by reducing tissue levels of ET-1 itself. In this
regard, interference with the stimulatory action of the local
RAS and even with autocrine mechanisms of stimulation,
has to be considered as a potential mode of action (32).
Endothelin and vascular wall perfusion. In addition to
the stimulation of VEGF production in vascular smooth
muscle cells and the proliferation of endothelial cells,
increase in tissue expression of ET-1 might lead to an
increase in the tone of vasa vasorum and a concomitant
decrease in vasa vasorum perfusion (33). Subsequently,
hypoxia might develop within the vascular wall, constituting
a potent stimulus for VEGF release, which might be further
enhanced by additional stimulation of ET-1 expression
(25,34). Indeed, in the same model of experimental hyper-
cholesterolemia used in this study, development of endo-
thelial dysfunction has been reported in the coronary circu-
lation on the level of both the macrovasculature and the
microvasculature and has been attributed, at least in part, to
the endogenous endothelin system due to the fact that
chronic administration of ET-A antagonist preserves endo-
thelial function on both these levels (10,11). Recent reports
confirm that vasa vasorum are sensitive to various vasoreac-
tive substances, among which ET-1 exerts a very strong
vasoconstrictive effect (35). Thus, in line with these findings
it may be speculated that attenuation of coronary neovas-
cularization by chronic endothelin receptor antagonism may
be secondary to preservation of endothelial function and
improvement of vascular perfusion.
Coronary neovascularization in experimental hypercho-
lesterolemia. In a primate model, progression of experi-
mental hypercholesterolemia has been shown to be associ-
ated with a marked increase in blood flow to the media of
coronary arteries as well as with a marked increase in flow
during adenosine-induced vasodilation (36). Conversely,
regression of hypercholesterolemia was associated with a
reversal of these alterations (37). Although formation of
new vasa vasorum rather than dilation of existing vessels was
suggested and a cause-and-effect relation with experimental
hypercholesterolemia was established on the basis of these
findings, further insight into the mechanisms underlying
these proliferative changes was pending. It has been sug-
gested that neovascularization of coronary vasa vasorum
might be triggered by structural alterations of the vascular
wall due to increase in lipid load and vessel thickness (14).
Indeed, experimental findings on the reduction in plaque
growth by inhibition of plaque neovascularization seem to
confirm an important role of vasa vasorum neovasculariza-
tion for afferent and efferent nutrient supply as well as for
the structural integrity of the arterial wall in the atheroscle-
rotic and pre-atherosclerotic disease state (38). However, in
a recent study, we found that coronary vasa vasorum
neovascularization precedes, rather than follows, atheroscle-
rotic lesion formation (15). Taking these, and the current,
results into consideration, an increase in spatial density of
coronary vasa vasorum in experimental hypercholesterol-
emia seems to result from active stimulation of neovascu-
larization rather than from passive adaptation to structural
alterations within the vascular wall. In this respect, the
increase in the vascular tissue expression of ET-1 in exper-
imental hypercholesterolemia might be of dual importance.
For, not only by increase in vascular tone of vasa vasorum
and subsequent decrease in vasa vasorum perfusion and
hypoxia within the vascular wall, but also by direct stimu-
lation of vascular smooth muscle cells, ET-1 can trigger the
release of potent angiogenic factors such as VEGF within
the vascular wall. Thus, experimental hypercholesterolemia
seems to provide an active stimulus for neovascularization of
coronary vasa vasorum with at least partial involvement of
the endogenous endothelin system, rather than leading to
vasa vasorum proliferation as an adaptive response second-
ary to structural alterations of the coronary arterial wall.
Study limitations. Although the definite nature of the
underlying stimuli and mechanisms for vasa vasorum neo-
vascularization in experimental hypercholesterolemia re-
mains to be determined, this study identifies the endoge-
nous endothelin system as an important pathophysiologic
element. Even if the potential temporary impact of hemo-
dynamics cannot be fully excluded due to lack of continuous
registration of hemodynamic parameters, we have previously
demonstrated no significance difference in hemodynamic
parameters between animals with and without chronic
ET-A antagonism in addition to a high cholesterol diet
(11). Furthermore, this study focused on the coronary
circulation, limiting the implications for other vascular beds.
Conclusions. This study, for the first time, demonstrates
that chronic endothelin receptor antagonism prevents the
increase in VEGF expression in the coronary arterial wall
as well as the increase in the spatial density of coronary
vasa vasorum in experimental hypercholesterolemia. Thus,
this study supports a role for the endogenous endothelin
system in coronary vasa vasorum neovascularization in
pathophysiologic disease states, such as hypercholesterol-
emia.
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